Display options
Cite
Labriet A, De Mattia E, Cecchin E, et al. Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. Front Pharmacol. 2017;8:712doi: 10.3389/fphar.2017.00712.
Labriet, A., De Mattia, E., Cecchin, E., Lévesque, �. �., Jonker, D., Couture, F., Buonadonna, A., D'Andrea, M., Villeneuve, L., Toffoli, G., & Guillemette, C. (2017). Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. Frontiers in pharmacology, 8712. https://doi.org/10.3389/fphar.2017.00712
Labriet, Adrien, et al. "Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L." Frontiers in pharmacology vol. 8 (2017): 712. doi: https://doi.org/10.3389/fphar.2017.00712
Labriet A, De Mattia E, Cecchin E, Lévesque É, Jonker D, Couture F, Buonadonna A, D'Andrea M, Villeneuve L, Toffoli G, Guillemette C. Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. Front Pharmacol. 2017 Oct 10;8:712. doi: 10.3389/fphar.2017.00712. eCollection 2017. PMID: 29066969; PMCID: PMC5641335.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2017 Oct 10;8:712. doi: 10.3389/fphar.2017.00712. eCollection 2017.

Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L.

Frontiers in pharmacology

Adrien Labriet, Elena De Mattia, Erika Cecchin, Éric Lévesque, Derek Jonker, Félix Couture, Angela Buonadonna, Mario D'Andrea, Lyne Villeneuve, Giuseppe Toffoli, Chantal Guillemette

Affiliations

  1. Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec Research Center, Québec, QC, Canada.
  2. Faculty of Pharmacy, Laval University, Québec, QC, Canada.
  3. Clinical and Experimental Pharmacology, IRCCS National Cancer Institute 'Centro di Riferimento Oncologico', Aviano, Italy.
  4. Centre Hospitalier Universitaire (CHU) de Québec Research Center, Québec, QC, Canada.
  5. Faculty of Medicine, Laval University, Québec, QC, Canada.
  6. Division of Medical Oncology, Department of Medicine, Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
  7. Medical Oncology Unit, IRCCS National Cancer Institute 'Centro di Riferimento Oncologico', Aviano, Italy.
  8. Medical Oncology Unit, San Filippo Neri Hospital, Rome, Italy.

PMID: 29066969 PMCID: PMC5641335 DOI: 10.3389/fphar.2017.00712

Abstract

Hepatocyte nuclear factor 1-alpha (HNF1A) is a liver-enriched transcription factor that plays a key role in many aspects of hepatic functions including detoxification processes. We examined whether

Keywords: hepatocyte nuclear factor 1-alpha; irinotecan; metastatic colorectal cancer; polymorphism; progression-free survival

References

  1. Xenobiotica. 2009 Jul;39(7):514-22 - PubMed
  2. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8170-4 - PubMed
  3. J Pharmacol Exp Ther. 2013 Apr;345(1):95-101 - PubMed
  4. Lipids Health Dis. 2015 Jul 25;14 :80 - PubMed
  5. Diabetologia. 2006 Jul;49(7):1545-51 - PubMed
  6. Pharmacogenomics J. 2016 Nov 15;: - PubMed
  7. Expert Opin Drug Metab Toxicol. 2016;12 (3):291-306 - PubMed
  8. J Clin Oncol. 2009 Jun 1;27(16):2604-14 - PubMed
  9. Pharmacogenet Genomics. 2014 Mar;24(3):177-83 - PubMed
  10. Pharmacogenomics J. 2015 Dec;15(6):513-20 - PubMed
  11. J Clin Endocrinol Metab. 2003 Jun;88(6):2548-51 - PubMed
  12. Biochem Res Int. 2014;2014:924105 - PubMed
  13. World J Gastroenterol. 2015 Nov 21;21(43):12234-48 - PubMed
  14. J Cell Sci. 2012 Jul 1;125(Pt 13):3133-43 - PubMed
  15. Nat Med. 2016 Mar;22(3):278-87 - PubMed
  16. Nat Genet. 2007 Jun;39(6):730-2 - PubMed
  17. Nat Genet. 2010 Jul;42(7):579-89 - PubMed
  18. J Proteomics. 2012 Jun 27;75(12):3386-99 - PubMed
  19. Pharmacogenomics. 2016 Sep;17 (14 ):1547-71 - PubMed
  20. Nat Commun. 2015 Jul 15;6:7754 - PubMed
  21. Nature. 1996 Dec 5;384(6608):455-8 - PubMed
  22. J Clin Oncol. 2009 May 20;27(15):2457-65 - PubMed
  23. Nat Genet. 2015 Dec;47(12):1415-25 - PubMed
  24. Diabetologia. 2006 Dec;49(12):2882-91 - PubMed
  25. Cancer Chemother Pharmacol. 1998;42 Suppl:S44-9 - PubMed
  26. Drug Metab Rev. 2014 Nov;46(4):421-58 - PubMed
  27. Am J Hum Genet. 2008 May;82(5):1193-201 - PubMed
  28. Bioinformatics. 2005 Jan 15;21(2):263-5 - PubMed
  29. Toxicol In Vitro. 2006 Mar;20(2):163-75 - PubMed
  30. Mol Pharmacol. 1999 May;55(5):921-8 - PubMed
  31. Science. 2004 Feb 27;303(5662):1378-81 - PubMed
  32. Biochem Biophys Res Commun. 2013 Nov 8;441(1):89-95 - PubMed
  33. Drug Metab Pharmacokinet. 2012;27(3):325-35 - PubMed
  34. Biochim Biophys Acta. 2005 Dec 20;1731(3):179-90 - PubMed
  35. J Pharmacol Exp Ther. 1997 Apr;281(1):304-14 - PubMed
  36. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):281-92 - PubMed
  37. Am J Hum Genet. 2007 Sep;81(3):559-75 - PubMed
  38. J Clin Oncol. 2006 Jul 1;24(19):3061-8 - PubMed
  39. J Mol Biol. 2001 Jul 13;310(3):635-58 - PubMed
  40. Pharmacogenet Genomics. 2015 Dec;25(12 ):573-83 - PubMed
  41. J Gene Med. 2017 Jan;19(1-2):null - PubMed
  42. Clin Pharmacol Ther. 2008 Sep;84(3):393-402 - PubMed
  43. Circ Cardiovasc Genet. 2009 Jun;2(3):244-54 - PubMed
  44. Biopharm Drug Dispos. 2016 Oct;37(7):421-432 - PubMed

Publication Types